ALHAMBRA, Calif., Dec. 19, 2024 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that leadership is participating in the J.P. Morgan 2025 Healthcare Conference, being held in San Francisco, on Tuesday, January 14, 2024, including a presentation at 10:30am PT from President and CEO of Astrana Health, Brandon Sim. The webcast link and related presentation materials will be available in the "IR Calendar" section of the Company's website: https://ir.astranahealth.com/news-events/ir-calendar.
About Astrana Health, Inc.
Astrana is a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all. Leveraging its proprietary end-to-end technology solutions, Astrana operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.
Headquartered in Alhambra, California, Astrana serves over 12,000 providers and over 1.1 million Americans in value-based care arrangements. Its subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), accountable care organizations (ACOs), and care delivery entities across primary, multi-specialty, and ancillary care. For more information, please visit www.astranahealth.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
Asher Dewhurst, ICR Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$31.42 |
Daily Change: | -1.28 -3.91 |
Daily Volume: | 52,625 |
Market Cap: | US$1.430B |
November 08, 2024 November 07, 2024 July 15, 2024 May 07, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load